Buscar resultados de ensayos clínicos
Metastatic Squamous Neck Cancer With Occult Primary - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Condición: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Fecha: 2015-12-07 Intervenciones: Drug: SF1126 |
Completed |
Nombre del estudio: Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Condición:
|
Active, not recruiting |
Nombre del estudio: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Condición:
|
Active, not recruiting |
Nombre del estudio: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Condición:
|
Completed |
Nombre del estudio: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Condición:
|
Terminated |
Nombre del estudio: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Condición:
|
Completed |
Nombre del estudio: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Condición:
|
Completed |
Nombre del estudio: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Condición:
|
Completed |
Nombre del estudio: Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Condición:
|
Active, not recruiting |
Nombre del estudio: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Condición:
|